Robert I. Horne

Robert I. Horne

Auto-generated profile, based on publicly available information

Robert I. Horne

University of Cambridge

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
FRFrancesco Simone Ruggeri
Francesco Simone Ruggeri
JHJohnny Habchi
Johnny Habchi
Sean ChiaSean Chia
Sean Chia
RHRobert I. Horne
Robert I. Horne
Michele VendruscoloMichele Vendruscolo
Michele Vendruscolo
Tuomas KnowlesTuomas Knowles
Tuomas Knowles
Significant efforts have been devoted in the last twenty years to developing compounds that can interfere with the aggregation pathways of proteins related to misfolding disorders, including Alzheimer’s and Parkinson’s diseases. However, no disease-modifying drug has become available for clinical use to date for these conditions. One of the main reasons for this failure is the incomplete knowledge of the molecular mechanisms underlying the process by which small molecules interact with protein aggregates and interfere with their aggregation pathways. Here, we leverage the single molecule morphological and chemical sensitivity of infrared nanospectroscopy to provide the first direct measurement of the structure and interaction between single Aβ42 oligomeric and fibrillar species and an aggregation inhibitor, bexarotene, which is able to prevent Aβ42 aggregation in vitro and reverses its neurotoxicity in cell and animal models of Alzheimer’s disease. Our results demonstrate that the carboxyl group of this compound interacts with Aβ42 aggregates through a single hydrogen bond. These results establish infrared nanospectroscopy as a powerful tool in structure-based drug discovery for protein misfolding diseases.

17 April 2024 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
RHRobert I. Horne
Robert I. Horne
EAEwa A. Andrzejewska
Ewa A. Andrzejewska
PAParvez Alam
Parvez Alam
ZBZ. Faidon Brotzakis
Z. Faidon Brotzakis
ASAnkit Srivastava
Ankit Srivastava
Michele VendruscoloMichele Vendruscolo
Michele Vendruscolo
Machine learning methods hold the promise to reduce the costs and the failure rates of conventional drug discovery pipelines. This issue is especially pressing for neurodegenerative diseases, where the development of disease-modifying drugs has been particularly challenging. To address this problem, we describe here a machine learning approach to identify small molecule inhibitors of α-synuclein aggregation, a process implicated in Parkinson’s disease and other synucleinopathies. Because the proliferation of α-synuclein aggregates takes place through autocatalytic secondary nucleation, we aim to identify compounds that bind the catalytic sites on the surface of the aggregates. To achieve this goal, we use structure-based machine learning in an iterative manner to first identify and then progressively optimize secondary nucleation inhibitors. Our results demonstrate that this approach leads to the facile identification of compounds two orders of magnitude more potent than previously reported ones.

18 December 2020 in Communications Chemistry
Verified
Journal Article
Open access
PDF file
RSRoxine Staats
Roxine Staats
TMThomas C. T. Michaels
Thomas C. T. Michaels
PFPatrick Flagmeier
Patrick Flagmeier
Sean ChiaSean Chia
Sean Chia
RHRobert I. Horne
Robert I. Horne
Michele VendruscoloMichele Vendruscolo
Michele Vendruscolo
The aggregation of α-synuclein is a central event in Parkinsons’s disease and related synucleinopathies. Since pharmacologically targeting this process, however, has not yet resulted in approved disease-modifying treatments, there is an unmet need of developing novel methods of drug discovery. In this context, the use of chemical kinetics has recently enabled accurate quantifications of the microscopic steps leading to the proliferation of protein misfolded oligomers. As these species are highly neurotoxic, effective therapeutic strategies may be aimed at reducing their numbers. Here, we exploit this quantitative approach to develop a screening strategy that uses the reactive flux toward α-synuclein oligomers as a selection parameter. Using this approach, we evaluate the efficacy of a library of flavone derivatives, identifying apigenin as a compound that simultaneously delays and reduces the formation of α-synuclein oligomers. These results demonstrate a compound selection strategy based on the inhibition of the formation of α-synuclein oligomers, which may be key in identifying small molecules in drug discovery pipelines for diseases associated with α-synuclein aggregation.

5 March 2025 in Nature Reviews Chemistry
Verified
Journal Article
Closed access
PDF file
RHRobert I. Horne
Robert I. Horne
SSSarah E. Sandler
Sarah E. Sandler
Michele VendruscoloMichele Vendruscolo
Michele Vendruscolo
UKUlrich F. Keyser
Ulrich F. Keyser

16 November 2023 in Journal of the American Chemical Society
Verified
Journal Article
Open access
SSSarah E. Sandler
Sarah E. Sandler
RHRobert I. Horne
Robert I. Horne
SRSara Rocchetti
Sara Rocchetti
RNRobert Novak
Robert Novak
NHNai-Shu Hsu
Nai-Shu Hsu
Michele VendruscoloMichele Vendruscolo
Michele Vendruscolo
Misfolded protein oligomers are of central importance in both the diagnosis and treatment of Alzheimer's and Parkinson's diseases. However, accurate high-throughput methods to detect and quantify oligomer populations are still needed. We present here a single-molecule approach for the detection and quantification of oligomeric species. The approach is based on the use of solid-state nanopores and multiplexed DNA barcoding to identify and characterize oligomers from multiple samples. We study α-synuclein oligomers in the presence of several small-molecule inhibitors of α-synuclein aggregation as an illustration of the potential applicability of this method to the development of diagnostic and therapeutic methods for Parkinson's disease.

14 August 2023 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
RHRobert I. Horne
Robert I. Horne
MMMichael A. Metrick
Michael A. Metrick
WMWing Man
Wing Man
DRDillon J. Rinauro
Dillon J. Rinauro
ZBZ. Faidon Brotzakis
Z. Faidon Brotzakis
Michele VendruscoloMichele Vendruscolo
Michele Vendruscolo
The accurate recapitulation in an in vitro assay of the aggregation process of α-synuclein in Parkinson's disease has been a significant challenge. As α-synuclein does not aggregate spontaneously in most currently used in vitro assays, primary nucleation is triggered by the presence of surfaces such as lipid membranes or interfaces created by shaking, to achieve aggregation on accessible time scales. In addition, secondary nucleation is typically only observed by lowering the pH below 5.8. Here we investigated assay conditions that enables spontaneous primary nucleation and secondary nucleation at pH 7.4. Using 400 mM sodium phosphate, we observed quiescent spontaneous aggregation of α-synuclein and established that this aggregation is dominated by secondary processes. Furthermore, the presence of potassium ions enhanced the reproducibility of quiescent α-synuclein aggregation. This work provides a framework for the study of spontaneous α-synuclein aggregation at physiological pH.